Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vilin Bio MedNSE:VILINBIO +4.93%69 EBITDA Margin % is 8.77% as of Mar. 2026, which is 22% above its 10-year median of 7.19. GuruFocus rates NSE:VILINBIO with a GF Score™ of 69/100 and a GF Value™ of ₹75.10 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 958 Drug Manufacturers companies, Vilin Bio Med ranks worse than 59.29% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Vilin Bio Med's EBITDA for the
six
months ended in Mar. 2026 was ₹28.6 Mil. Vilin Bio Med's Revenue for the
six
months ended in Mar. 2026 was ₹326.0 Mil. Therefore, Vilin Bio Med's EBITDA margin for the quarter that ended in Mar. 2026 was 8.77%.
Vilin Bio Med (NSE:VILINBIO) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Vilin Bio Med EBITDA Margin % Related Terms
Vilin Bio Med EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Vilin Bio Med's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vilin Bio Med's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vilin Bio Med EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vilin Bio Med's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Vilin Bio Med's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vilin Bio Med (NSE:VILINBIO) has a EBITDA Margin % of 8.77% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vilin Bio Med and its competitors. This is 22% above median its historical median of 7.19. Over the past decade, Vilin Bio Med's EBITDA Margin % has ranged from 5.27 to 21.10. According to the industry distribution chart, Vilin Bio Med ranks #568 out of 958 companies in the Drug Manufacturers industry, placing it in the top 59.3%.
Is Vilin Bio Med's EBITDA Margin % too high?
Vilin Bio Med's current EBITDA Margin % of 8.77% is 22% above median its 10-year median of 7.19. Over the past 10 years, this metric has ranged from a low of 5.27 to a high of 21.10. The Drug Manufacturers industry median EBITDA Margin % is 12.01. Vilin Bio Med's value of 8.77% is 26.9% below this industry median. Based on the distribution chart, Vilin Bio Med ranks #568 out of 958 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Vilin Bio Med has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vilin Bio Med's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vilin Bio Med ranks #568 out of 958 companies for EBITDA Margin %. This places Vilin Bio Med in the lower half of its industry. The industry median EBITDA Margin % is 12.01. Vilin Bio Med's value of 8.77% is 26.9% below this benchmark. Historically, Vilin Bio Med's own EBITDA Margin % has ranged from 5.27 to 21.10 over the past decade. While the company's 10-year median is 7.19 vs. the industry median of 12.01, Vilin Bio Med has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.01, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vilin Bio Med's current EBITDA Margin % of 8.77% is 26.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vilin Bio Med and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vilin Bio Med's current EBITDA Margin % is 8.77%, which is 22% above median its own 10-year median of 7.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vilin Bio Med stock overvalued right now?
Based on GuruFocus' analysis, Vilin Bio Med (NSE:VILINBIO) is currently considered Possible Value Trap. The stock's GF Value™ is ₹75.10, compared to a current price of ₹44.70 — trading 40.5% below its estimated fair value. The current EBITDA Margin % is 8.77%, which is 22% above median its 10-year median of 7.19 and 26.9% below the Drug Manufacturers industry median of 12.01. Vilin Bio Med's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Vilin Bio Med (NSE:VILINBIO), the current EBITDA Margin % is 8.77% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vilin Bio Med (NSE:VILINBIO) Overvalued in 2026?
Based on GuruFocus' analysis, Vilin Bio Med stock appears to be undervalued.
The current stock price of ₹44.70 is trading 40.5% below its estimated GF Value™ of ₹75.10.
GuruFocus considers Vilin Bio Med to be Possible Value Trap.
Key valuation signals for NSE:VILINBIO:
EBITDA Margin %: 8.77% (22% above median its 10-year median of 7.19)
GF Value™: ₹75.10 vs. price of ₹44.70 (40.5% below fair value)
Industry Position: 26.9% below the Drug Manufacturers median (#568 of 958)
No single metric tells the full story. See the NSE:VILINBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vilin Bio Med Ltd is engaged in the domestic business of manufacturing Pharmaceuticals products. It is manufacturing pharmaceutical formulations such as Oral Liquids, Dry syrups, Sachets, External Preparations, Beta and Non-Beta Lactam tablets, and Capsules and Nutritional Food supplements.
69GF Score
Get the complete analysis for NSE:VILINBIO
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:VILINBIO has been successfully added to your 
